智通财经APP获悉，诺诚健华-B(09969)盘初走高，升约6%。旗下新型CD19单抗创新药Tafasitamab已纳入多个省市的18项地方商保的海外特药目录。公司即将公布FGFR抑制剂Gunagratinib（ICP-192）治疗胆管癌的最新研究数据。截至发稿，诺诚健华5.96%，报14.58港元，成交额0.10亿港元。
日前，诺诚健华宣布，目前，新型CD19单抗创新药Tafasitamab已纳入多个省市的18项地方商保的海外特药目录。公司还在将在1月19日-21日召开的2023年美国临床肿瘤学会胃肠癌研讨会（ASCO GI）公布FGFR抑制剂Gunagratinib（ICP-192）治疗胆管癌的最新研究数据。中信证券最新评论称，公司奥布替尼其他适应症正常进行，多里程碑事件有望近一年陆续落地。多款药物在血液瘤、实体瘤和自免领域取得积极进展，不断完善公司适应症布局。维持“买入”评级。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.